FilingReader Intelligence
Pharmablock reports 23% revenue growth despite profit decline
August 7, 2025 at 05:26 PM UTC•By FilingReader AI
Pharmablock Sciences reported first-half revenue of RMB 919.7 million, up 23.48% year-on-year, but net profit attributable to shareholders fell 26.54%. Total assets grew 11.93%.
The company announced its convertible bonds are approaching conditional redemption.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Summary table of non-operating fund occupation and other related party fund transactions for Pharmaron Beijing Co., Ltd. in the first half of 2025August 7, 2025 at 08:00 AM UTC
Announcement regarding the provision for asset impairment in the first half of 2025August 7, 2025 at 08:00 AM UTC
Announcement regarding the amendment of the company's business scope, the change of the company's registered capital, and the revision of the articles of associationAugust 7, 2025 at 08:00 AM UTC
Indicative announcement regarding Yaoshi convertible bond expected to meet redemption conditionsAugust 7, 2025 at 08:00 AM UTC
Announcement of board resolutionsAugust 7, 2025 at 08:00 AM UTC
Announcement on the proposed change of accounting firmAugust 7, 2025 at 08:00 AM UTC
Announcement of the board of supervisors' resolutionAugust 7, 2025 at 08:00 AM UTC
2025 semi-annual report summaryAugust 7, 2025 at 08:00 AM UTC
Special report on the storage and use of raised funds for the first half of 2025August 7, 2025 at 08:00 AM UTC
SZSE:300725•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Pharmablock Sciences (Nanjing) publishes news
Free account required • Unsubscribe anytime